News | August 05, 2024
Roche closes acquisition of LumiraDx’s Point of Care technology
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Subscribe To Our Newsletter & Stay Updated
